167 related articles for article (PubMed ID: 33791917)
1. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.
Takeda T; Sasaki T; Suzumori C; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Int J Clin Oncol; 2021 Jul; 26(7):1293-1303. PubMed ID: 33791917
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel.
Takeda T; Sasaki T; Okamoto T; Ishitsuka T; Yamada M; Nakagawa H; Mie T; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Pancreatology; 2023 Apr; 23(3):275-282. PubMed ID: 36792473
[TBL] [Abstract][Full Text] [Related]
3. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study.
Suzuki Y; Saito K; Nakai Y; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Takahara N; Tateishi R; Fujishiro M
Support Care Cancer; 2023 Mar; 31(3):197. PubMed ID: 36862196
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Asama H; Ueno M; Kobayashi S; Fukushima T; Kawano K; Sano Y; Tanaka S; Nagashima S; Morimoto M; Ohira H; Maeda S
Pancreas; 2022 Feb; 51(2):148-152. PubMed ID: 35404889
[TBL] [Abstract][Full Text] [Related]
5. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan.
Furuse J; Osugi F; Machii K; Niibe K; Endo T
Int J Clin Oncol; 2024 Apr; 29(4):456-463. PubMed ID: 38353906
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study.
Tozuka Y; Ueno M; Kobayashi S; Morimoto M; Fukushima T; Sano Y; Kawano K; Hanaoka A; Tezuka S; Asama H; Moriya S; Morinaga S; Ohkawa S; Maeda S
Oncol Lett; 2022 Oct; 24(4):375. PubMed ID: 36238838
[TBL] [Abstract][Full Text] [Related]
7. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
8. Improved prognosis of pancreatic cancer patients with peritoneal metastasis.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Pancreatology; 2021 Aug; 21(5):903-911. PubMed ID: 33766484
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy.
Kurita Y; Kobayashi N; Tokuhisa M; Goto A; Kubota K; Endo I; Nakajima A; Ichikawa Y
Pancreatology; 2019 Jan; 19(1):127-135. PubMed ID: 30473464
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(5):728-736. PubMed ID: 33611490
[TBL] [Abstract][Full Text] [Related]
11. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
Pijnappel EN; Dijksterhuis WPM; van der Geest LG; de Vos-Geelen J; de Groot JWB; Homs MYV; Creemers GJ; Mohammad NH; Besselink MG; van Laarhoven HWM; Wilmink JW;
J Natl Compr Canc Netw; 2021 Aug; 20(5):443-450.e3. PubMed ID: 34450595
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
[TBL] [Abstract][Full Text] [Related]
13. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study.
da Rocha IMG; Marcadenti A; de Medeiros GOC; Bezerra RA; Rego JFM; Gonzalez MC; Fayh APT
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):445-454. PubMed ID: 30924270
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites.
Inoue K; Fukushi K; Yamaguchi S; Taira T; Shibuki T; Satake T; Watanabe K; Sasaki M; Imaoka H; Mitsunaga S; Ikeda M
Pancreatology; 2024 Apr; ():. PubMed ID: 38599956
[TBL] [Abstract][Full Text] [Related]
15. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.
Zhang B; Zhou F; Hong J; Ng DM; Yang T; Zhou X; Jin J; Zhou F; Chen P; Xu Y
World J Surg Oncol; 2021 Jun; 19(1):182. PubMed ID: 34154596
[TBL] [Abstract][Full Text] [Related]
16. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Uemura S; Iwashita T; Ichikawa H; Iwasa Y; Mita N; Shiraki M; Shimizu M
Br J Nutr; 2021 May; 125(10):1140-1147. PubMed ID: 32883372
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of the cachexia index in patients with small cell lung cancer.
Go SI; Park MJ; Lee GW
BMC Cancer; 2021 May; 21(1):563. PubMed ID: 34001060
[TBL] [Abstract][Full Text] [Related]
18. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective study based on a large population.
Shen XD; Wang X; Zheng ZJ; Chen YH; Tan CL; Liu XB; Ke NW
Cancer Med; 2023 May; 12(9):10438-10448. PubMed ID: 36938648
[TBL] [Abstract][Full Text] [Related]
19. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
[TBL] [Abstract][Full Text] [Related]
20. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
